Director Gillian Cannon resigns from Corcept board; consulting agreement signed

CORCEPT THERAPEUTICS INC

Dr. Gillian Cannon resigned from the Board effective October 10, 2025, with no disagreement over operations or policies.
Company and Cannon entered consulting agreement from effective date until 2026 annual stockholder meeting.
Consulting fee: $5,708.33 per month; previously awarded stock options continue vesting per original schedule.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.